Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jubilant Ingrevia's Days Sales Outstanding for the
three
months ended in Mar. 2026 was 61.24.
Jubilant Ingrevia's Days Inventory for the
three
months ended in Mar. 2026 was 129.77.
Jubilant Ingrevia's Days Payable for the
three
months ended in Mar. 2026 was 138.72.
Therefore, Jubilant Ingrevia's Cash Conversion Cycle (CCC) for the
three
months ended in Mar. 2026 was 52.29.
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Jubilant Ingrevia Cash Conversion Cycle Related Terms
Jubilant Ingrevia Cash Conversion Cycle Historical Data
* Premium members only.
The historical data trend for Jubilant Ingrevia's Cash Conversion Cycle can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:543271 vs LIN, SHW, ECL: Cash Conversion Cycle Comparison
For the Specialty Chemicals subindustry, Jubilant Ingrevia's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jubilant Ingrevia Cash Conversion Cycle vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Jubilant Ingrevia's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Jubilant Ingrevia's Cash Conversion Cycle falls into.
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
Jubilant Ingrevia's Cash Conversion Cycle for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jubilant Ingrevia (BOM:543271) has a Cash Conversion Cycle of 52.29 as of Mar. 2026. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jubilant Ingrevia and its competitors.
Is Jubilant Ingrevia's Cash Conversion Cycle too high?
Jubilant Ingrevia's current Cash Conversion Cycle is 52.29. The Chemicals industry median Cash Conversion Cycle is 89.20. Jubilant Ingrevia's value of 52.29 is 41.4% below this industry median. Overall, Jubilant Ingrevia has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Jubilant Ingrevia's Cash Conversion Cycle compare to LIN and SHW?
Jubilant Ingrevia's Cash Conversion Cycle of 52.29 can be compared against companies in the Chemicals industry. The industry median Cash Conversion Cycle is 89.20. Jubilant Ingrevia's value of 52.29 is 41.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Chemicals company?
The median Cash Conversion Cycle among Chemicals companies is 89.20, based on 1,579 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jubilant Ingrevia's current Cash Conversion Cycle of 52.29 is 41.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Jubilant Ingrevia and its competitors. For the Chemicals industry, the median Cash Conversion Cycle is 89.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jubilant Ingrevia's current Cash Conversion Cycle is 52.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jubilant Ingrevia stock overvalued right now?
Based on GuruFocus' analysis, Jubilant Ingrevia (BOM:543271) is currently considered Fairly Valued. The stock's GF Value™ is ₹704.91, compared to a current price of ₹740.10 — trading 5% above its estimated fair value. The current Cash Conversion Cycle is 52.29 and 41.4% below the Chemicals industry median of 89.20. Jubilant Ingrevia's overall GF Score™ is 79/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Jubilant Ingrevia (BOM:543271), the current Cash Conversion Cycle is 52.29 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jubilant Ingrevia (BOM:543271) Overvalued in 2026?
Based on GuruFocus' analysis, Jubilant Ingrevia stock appears to be overvalued.
The current stock price of ₹740.10 is trading 5% above its estimated GF Value™ of ₹704.91.
GuruFocus considers Jubilant Ingrevia to be Fairly Valued.
Key valuation signals for BOM:543271:
Cash Conversion Cycle: 52.29
GF Value™: ₹704.91 vs. price of ₹740.10 (5% above fair value)
Industry Position: 41.4% below the Chemicals median
No single metric tells the full story. See the BOM:543271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jubilant Ingrevia Ltd is a life science products and solutions provider in the chemicals industry. It serves Pharmaceutical, Nutrition, Agrochemical, Consumer, and Industrial customers with its customized products and solutions. Its segments are Specialty chemicals, Nutrition & Health solutions, and Chemical Intermediates. The maximum revenue for the company is generated from its Specialty chemicals segment, which includes Bio-Pyridine & Bio-Picolines, Fine chemicals, Agro chemicals, Custom development and manufacturing organization, Microbial control solutions.. Geographically, it derives key revenue from India and the rest from the Americas and Europe, China, and the Rest of the world.
79GF Score
Get the complete analysis for BOM:543271
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543271 has been successfully added to your 
